Determination of a novel and potent cyclic GMP phosphodiesterase inhibitor, 4-([3,4-(methylenedioxy)-benzyl]amino)-6,7,8-trimethoxyquinazoline, in dog plasma by high-performance liquid chromatography.
A simple and accurate method for determining levels of 4-([3,4-(methylenedioxy)benzyl]amino)-6,7,8-trimethoxyquinazoline, a novel cyclic GMP phosphodiesterase inhibitor, in dog plasma was developed. This method involves extraction with diethyl ether and reversed-phase high-performance liquid chromatography with ultraviolet detection. Regression analysis showed that the method was linear over the range 1.0-1000 ng/ml. The method was employed for the analysis of plasma samples in a preliminary pharmacokinetic study in beagle dogs.
Tokumura
T
T
Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan.
Takase
Y
Y
Horie
T
T
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000818:Animals; D002851:Chromatography, High Pressure Liquid / Q000379:methods* / Q000706:statistics & numerical data; D004285:Dogs; D011786:Quality Control; D011799:Quinazolines / Q000097:blood* / Q000493:pharmacokinetics; D012044:Regression Analysis; D012680:Sensitivity and Specificity
D011799:Quinazolines; C084663:4-((3,4-(methylenedioxy)benzyl)amino)-6,7,8-trimethoxyquinazoline; D015106:3',5'-Cyclic-GMP Phosphodiesterases